To continue reading this content, please enable JavaScript in your browser settings and refresh this page. Preview this article 1 min DraftKings will move its ...

JPMorgan Chase & Co. plans to move its Boston offices to the new South Station Tower — and join the rarefied ranks of companies that have stamped their names on the city’s skyline. In a sign of its ...

Dec 8 (Reuters) - Recursion Pharma (RXRX.O), opens new tab, which uses artificial intelligence to discover new drug candidates, said on Monday its experimental oral drug helped reduce abnormal growths ...

Shares of Recursion Pharmaceuticals, Inc. (NASDAQ: RXRX) are trading higher Monday after the pharmaceutical company reported positive data from an ongoing trial. What To Know: Recursion ...

Getting in on the ground floor would be great, but only if there's massive upside ahead for the company. Several stocks on the market offer investors the opportunity to capitalize on the rapidly ...

Jeffrey is a freelance features writer at Collider. He is an MPA-accredited entertainment journalist and a Tomatometer-approved critic based in the LA area. He graduated from the University of Texas ...

Andrew Joseph covers health, medicine, and the biopharma industry in Europe. You can reach Andrew on Signal at drewqjoseph.45. LONDON — In the year-plus since Najat Khan joined the AI-focused drug ...

Recursion Pharmaceuticals, Inc. leverages AI to accelerate drug discovery, offering both a licensing platform and an internal drug development pipeline. RXRX faces heavy competition, ongoing operating ...

After a challenging 12 years trying to use AI to create new medicines, cofounder Chris Gibson stepped down as CEO last week. Can R&D chief and new CEO Najat Khan turn it around? In 2014, Recursion ...

Investors in Recursion (NASDAQ: RXRX) seemed only mildly fazed by Wednesday’s series of company announcements. The artificial intelligence (AI)-based drug developer’s stock barely moved on Wednesday, ...

To continue reading this content, please enable JavaScript in your browser settings and refresh this page. Preview this article 1 min The Boston Harbor Hotel is ...

After 12 years leading Utah-based techbio company Recursion, CEO Chris Gibson is stepping down. Recursion’s R&D head and Chief Commercial Officer Najat Khan will become CEO effective Jan. 1. Gibson co ...